These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 2118431

  • 41. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 42. Effects of peptide 6A on coronary blood flow dynamics in canine coronary thrombosis.
    Mehta JL, Nichols WW, Saldeen TG.
    J Cardiovasc Pharmacol; 1989 Jun; 13(6):803-11. PubMed ID: 2484073
    [Abstract] [Full Text] [Related]

  • 43. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA, Abrahamsson TI, Nerme VK, Mattsson CJ.
    Thromb Res; 2005 Jun; 116(6):519-24. PubMed ID: 16181987
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 47. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M, Ichikawa Y, Yatani A, Matsui K, Nakahara H, Kaneko M, Sakurama T, Ueshima S, Matsuo O.
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
    [Abstract] [Full Text] [Related]

  • 48. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS.
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [Abstract] [Full Text] [Related]

  • 49. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
    Mattsson C, Björkman JA, Abrahamsson T, Nerme V, Schatteman K, Leurs J, Scharpé S, Hendriks D.
    Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS, Bentley RG, Morgan SR, Kasiewski CJ, Chu V, Perrone MH, Leadley RJ.
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [Abstract] [Full Text] [Related]

  • 53. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

  • 54. The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
    Mino T, Suzuki J, Hayashi H.
    Jpn J Pharmacol; 1989 Aug; 50(4):429-33. PubMed ID: 2476578
    [Abstract] [Full Text] [Related]

  • 55. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Komjathy SF, Poulton J, Stafford JL, Godard J.
    Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
    [Abstract] [Full Text] [Related]

  • 56. New developments in thrombolytic therapy.
    Collen D, Gold HK.
    Adv Exp Med Biol; 1990 Jan; 281():333-54. PubMed ID: 2129372
    [Abstract] [Full Text] [Related]

  • 57. Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.
    McAuliffe SJ, Moors JA, Jones HB.
    Br J Pharmacol; 1994 May; 112(1):272-6. PubMed ID: 8032650
    [Abstract] [Full Text] [Related]

  • 58. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.